Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Triple vs Dual Therapy in COPD
NCT02164513Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial of fluticasone in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Annual Rate of On-treatment Moderate/Severe Exacerbations at 52 weeks. Started Jun 2014; status: completed.
02
Drugs
fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02164513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164513.